US equities |
SPCX $167.42 ▲+5.32% NVDA $236.30 ▲+1.00% MU $1,066.09 ▼-0.82% TSLA $378.40 ▲+2.11% MSFT $526.42 ▲+1.72% SNDK $1,709.68 ▼-0.60% INTC $117.37 ▼-1.65% META $744.23 ▲+2.22%
FinancialContent

Compass Therapeutics, Inc. - Common Stock (NQ:CMPX)

0.9297 +0.0730 (+8.52%)
Delayed Quote Updated: 12:43 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Compass Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
From Compass Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 Next >